 |
|
|
|
|
||||||||||||
|
||||||||||||||||
|
||||||||||||||||
 |
||||||||||||||||
|
||||||||||||||||
|
|
|
|
EPS Co., Ltd.
In November 2003 EPS and Sosei agreed on an alliance for clinical development services.
Itochu
Corporation
Itochu and Sosei have agreed on a capital alliance and enter into a strategic collaboration for biopharmaceutical business opportunities.
For more information regarding this alliance, please
go to the news
release
Sosei licensed to Mundipharma the commercialisation rights of AD 923 in Europe and other international markets, excluding north America and Japan. For more information regarding this alliance, please
go to the news
release
Arakis (now Sosei R&D Ltd.) licensed exclusive worldwide development and commercialization rights for NVA237 to Novartis in a deal announced 13 April 2005 For more information regarding this alliance, please
go to the news release
|
|
|
|
 |
 |
|
|
|
|
 |